Table 2.

Racial and ethnic differences in aspirin and statin use by cardiovascular risk

	Estimated prevalence (%)*				Relative risk† (95% CI)
Risk group‡	Overall	White, non-Hispanic	Black, non-Hispanic	Hispanic, non-black	Black, non-Hispanic vs. White, non-Hispanic	Hispanic, non-black vs. White, Non-Hispanic
High risk (N = 1066)
Statin use	48	50	38	46	0.77 (0.63, 0.94)	0.94 (0.70, 1.18)
Aspirin use	41	44	29	30	0.67 (0.48, 0.90)	0.69 (0.43, 1.03)
Moderate risk (N = 977)
Statin use	22	23	14	21	0.60 (0.36, 0.96)	0.92 (0.54, 1.47)
Aspirin use	19	19	16	8	0.84 (0.51, 1.31)	0.40 (0.17, 0.90)
Low risk (N = 812)
Statin use	27	27	24	28	0.88 (0.55, 1.33)	1.04 (0.60, 1.64)
Aspirin use	24	26	17	15	0.64 (0.38, 1.03)	0.58 (0.27, 1.13)

^*Estimates are weighted to account for differential probabilities of selection and differential non-response.

^†Estimated relative risks and confidence intervals obtained using method described in Zhang and Yu (1998).

^‡Excludes 39 respondents from analytic sample who could not be assigned to a risk group due to missing data.